Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PROSHARES TRUST (ZBIO) Total Current Liabilities: 2023-2024

Historic Total Current Liabilities for Zenas BioPharma (ZBIO) over the last 2 years, with Dec 2024 value amounting to $57.3 million.

  • Zenas BioPharma's Total Current Liabilities rose 19.15% to $52.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $52.4 million, marking a year-over-year increase of 19.15%. This contributed to the annual value of $57.3 million for FY2024, which is 146.33% up from last year.
  • Per Zenas BioPharma's latest filing, its Total Current Liabilities stood at $57.3 million for FY2024, which was up 146.33% from $23.3 million recorded in FY2023.
  • Zenas BioPharma's Total Current Liabilities' 5-year high stood at $57.3 million during FY2024, with a 5-year trough of $23.3 million in FY2023.
  • Its 2-year average for Total Current Liabilities is $40.3 million, with a median of $40.3 million in 2023.
  • Data for Zenas BioPharma's Total Current Liabilities shows a peak YoY surged of 146.33% (in 2024) over the last 5 years.
  • Zenas BioPharma's Total Current Liabilities (Yearly) stood at $23.3 million in 2023, then skyrocketed by 146.33% to $57.3 million in 2024.